Compare American International Group Inc (AIG) vs Biogen Inc (BIIB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American International Group Inc vs Biogen Inc — how do they compare? American International Group Inc trades at $79.57 (market cap $42.98B), while Biogen Inc trades at $201.76 (market cap $30.37B). The key difference: American International Group Inc is the larger of the two by market cap, and American International Group Inc pays a 2.47% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| AIG | BIIB | |
|---|---|---|
Market Cap | $42.98B | $30.37B |
Sector | Financials | Health |
52-Week High | $86.59 | $216.63 |
52-Week Low | $71.89 | $122.68 |
Enterprise Value | $50.68B | $32.65B |
Dividend Yield | 2.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIG trades at $81.06, up 2.1% today, showing strong momentum with three consecutive quarterly earnings beats. The stock is supported by bullish technical signals and a consensus price target of $88.13. Recent executive appointments and the acquisition of Everest Colombia signal strategic growth initiatives. Revenue stabilized around $26.8B in 2025 with net income margin improving to 11.88%.
Outlook remains positive with earnings growth and expansion in Latin America offering upside potential. Risks include catastrophe exposure and competitive pressures. Analysts are predominantly neutral with 58.5% Hold ratings, suggesting cautious optimism amid solid fundamentals.
Biogen (BIIB) trades at $205.70, down 4.82% today, with a bullish technical signal and strong earnings beat history. The stock shows solid fundamentals with a P/E of 22.42, net income margin of 13.81%, and positive cash flow trends. Recent acquisitions like RayThera for up to $1 billion aim to expand its immunology pipeline, while Alzheimer's portfolio updates at AAIC 2026 provide near-term catalysts. Analyst consensus is bullish with a $224.82 price target, though legal investigations and legacy drug sales declines pose headwinds.
The outlook remains positive given earnings momentum and strategic pipeline investments, but investors face risks from ongoing legal probes and competitive pressures. The stock offers upside to consensus targets if new drug launches offset revenue declines, but volatility may persist amid sector rotation and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American International Group Inc
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. Its revenue is split roughly evenly between commercial and consumer lines.
Read more on AIG →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
